Post-COVID Syndrome in Non-hospitalised Patients with COVID-19: a Longitudinal Prospective Cohort Study
Overview
Authors
Affiliations
Background: While the leading symptoms during coronavirus disease 2019 (COVID-19) are acute and the majority of patients fully recover, a significant fraction of patients now increasingly experience long-term health consequences. However, most data available focus on health-related events after severe infection and hospitalisation. We present a longitudinal, prospective analysis of health consequences in patients who initially presented with no or minor symptoms of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection. Hence, we focus on mild COVID-19 in non-hospitalised patients.
Methods: 958 Patients with confirmed SARS-CoV-2 infection were observed from April 6th to December 2nd 2020 for long-term symptoms and SARS-CoV-2 antibodies. We identified anosmia, ageusia, fatigue or shortness of breath as most common, persisting symptoms at month 4 and 7 and summarised presence of such long-term health consequences as post-COVID syndrome (PCS). Predictors of long-term symptoms were assessed using an uni- and multivariable logistic regression model.
Findings: We observed 442 and 353 patients over four and seven months after symptom onset, respectively. Four months post SARS-CoV-2 infection, 8•6% (38/442) of patients presented with shortness of breath, 12•4% (55/442) with anosmia, 11•1% (49/442) with ageusia and 9•7% (43/442) with fatigue. At least one of these characteristic symptoms was present in 27•8% (123/442) and 34•8% (123/353) at month 4 and 7 post-infection, respectively. A lower baseline level of SARS-CoV-2 IgG, anosmia and diarrhoea during acute COVID-19 were associated with higher risk to develop long-term symptoms.
Interpretation: The on-going presence of either shortness of breath, anosmia, ageusia or fatigue as long-lasting symptoms even in non-hospitalised patients was observed at four and seven months post-infection and summarised as post-COVID syndrome (PCS). The continued assessment of patients with PCS will become a major task to define and mitigate the socioeconomic and medical long-term effects of COVID-19.
Funding: COVIM:"NaFoUniMedCovid19"(FKZ: 01KX2021).
NETosis: A key player in autoimmunity, COVID-19, and long COVID.
Monsalve D, Acosta-Ampudia Y, Acosta N, Celis-Andrade M, Sahin A, Yilmaz A J Transl Autoimmun. 2025; 10:100280.
PMID: 40071133 PMC: 11894324. DOI: 10.1016/j.jtauto.2025.100280.
Myocardial Dysfunction and Risk of Long COVID in Patients Recovered From Mild and Moderate COVID-19.
Zhou B, Zhang Y, Han S, Zhang J, Song L, Wang H Echocardiography. 2025; 42(3):e70120.
PMID: 40029146 PMC: 11875044. DOI: 10.1111/echo.70120.
Han E, Muller-Zlabinger K, Hasimbegovic E, Poschenreithner L, Kastner N, Maleiner B Biomolecules. 2025; 15(2).
PMID: 40001603 PMC: 11853648. DOI: 10.3390/biom15020300.
Identification of a multi-omics factor predictive of long COVID in the IMPACC study.
Gabernet G, Maciuch J, Gygi J, Moore J, Hoch A, Syphurs C bioRxiv. 2025; .
PMID: 39990442 PMC: 11844572. DOI: 10.1101/2025.02.12.637926.
Melo J, Silva A, Yamamoto L, Ferreira T, Luvizutto G, Neves F Braz J Infect Dis. 2025; 29(2):104509.
PMID: 39978115 PMC: 11889545. DOI: 10.1016/j.bjid.2025.104509.